Abbott Laboratories
ABT · NYSE
ABT · NYSE
Consensus is Buy across 20 analysts. The supplied target table reports a $120 mean, a $125 low, and a $125 high, so the stated range is unusually narrow and internally inconsistent with the mean; no conventional target spread can be established from those figures. Among named analysts, TD Cowen is the most bullish with a maintained $135 target. The least bullish analyst is not identified. Direction over the past week was broadly unchanged: TD Cowen reiterated its view and maintained its target, while no other weekly revisions are supplied. The evidence does not establish a substantive analyst disagreement beyond TD Cowen’s higher target and the conflicting aggregate figures.
| Firm | Analyst | Rating | Price Target | Upside | Date | Source |
|---|---|---|---|---|---|---|
| Freedom Broker | — | $120 | +16.4% | Jan 29, 2026 | Open the report this row came from | |
| UBS | — | $125 | +21.3% | Oct 17, 2023 |
